To provide an overview of recently published articles describing or applying newer methods for evaluating comparative effectiveness research (CER) in rheumatoid arthritis (RA).
INTRODUCTION
Comparative effectiveness research (CER) seeks to inform healthcare decisions by providing evidence of the effectiveness, benefits and harms of different treatment options [1] . The management of rheumatoid arthritis (RA) has progressed dramatically in recent years through the development of multiple efficacious biologic and nonbiologic agents. However, few comparative data are available to allow clinicians, patients and other stakeholders to assess the risks and benefits of various therapies to guide optimal decisions for individual patients [2] . Further research to examine the comparative effectiveness of different biologic therapies for RA was listed as one of the top 25 priority research topics by the Institute of Medicines (IOM) [3] .
A number of methodologies are available to examine CER questions in RA and other chronic diseases [4] . These include head-to-head clinical trials; synthesis of clinical trials through metaanalyses or related techniques; and studies using observational data. In this review, methodologies that have been or might be used for CER in RA will be described, drawing whenever possible on examples from recent arthritis clinical trials, metaanalyses and observational studies.
CLINICAL TRIALS IN RHEUMATOID ARTHRITIS
Traditional randomized controlled trials (RCTs) typically have used placebos as comparison groups and excluded clinically relevant patient subgroups such as older patients and those with high comorbidities [5] ; so, most of them are not adequate to
The AMPLE (Abatacept versus Adalimumab comparison in Biologic Naive Subjects with Background Methotrexate) study is one of the first head-to-head, noninferiority studies of biologics in RA patients. It compared the efficacy and safety of subcutaneous abatacept vs. adalimumab (ADA), both with background methotrexate (MTX). A key design element is that it was powered to demonstrate noninferiority at a 12% margin, meaning that the lower bound of the 95% confidence interval (CI) had to exclude 12% in order for abatacept to be considered noninferior to ADA. This study [8 && ] found that the ACR20 response rates were 64.8% for abatacept and 63.4% for ADA, a difference estimate of 1.8% (95% CI À5.6 to 9.2), indicating that abatacept was noninferior to ADA. This design must establish a noninferiority margin (a difference) that must be defended on clinical grounds, and guidelines for choosing this difference are not consistent. Noninferiority margins in the 10-12% range have been used in some past studies and have been accepted by the U.S. Food and Drugs Administration (FDA) and European Medicines Agency [9] . Moreover, noninferiority trials are generally large (such as AMPLE, with a size of 646 patients), usually larger than a trial designed to show superiority, because they must exclude a small degree of inferiority compared with an active comparator drug.
In contrast, the ADACTA (ADAlimumab and ACTAmra) trial was designed to show the superiority of monotherapy with tocilizumab (TCZ) vs. ADA for RA. As a superiority study, its sample size was substantially smaller (n ¼ 325) than in the AMPLE trial. The results of this study showed that TCZ was superior to ADA in the change in DAS28 (À3.3 vs. À1.8, P < 0.001). Because manufacturers typically do not make available to investigators matching placebo versions of their products [10] , blinding the administration of parenteral TCZ and subcutaneous ADA was one particular challenge for the ADACTA trial [11] . In addition to a blinded clinical assessor, patients in this study were blinded by placing a physical barrier (e.g. towel, pillow) between the patient's field of vision and the site of injection; investigators were further masked to the laboratory value of C-reaction protein, which was felt to have the potential to unblind the trial. These requirements for blinding pose particular challenges in future head-to-head studies of subcutaneous products where manufacturers generally do not make available blinded placebo in identical appearing syringes.
Treatment of Early Aggressive Rheumatoid Arthritis (TEAR) trial [12 & ], by using a two-by-two factorial design, randomly assigned patients to one of the four treatment arms: immediate MTX along with etanercept, immediate oral triple therapy (MTX along with sulfasalazine along with hydroxychloroquine) or step-up from MTX monotherapy to one of the two combination therapies at week 24. The factorial design tests the marginal effects of each treatment strategy and requires a smaller sample size than a typical four-arm parallel group design [11] . On the basis of DAS28-ESR change from week 48 to week 102, this study found no clinical differences between the two treatment approaches. Similarly, the RACAT (Rheumatoid Arthritis: Comparison of Active Therapies) trial also found that the strategy of MTX and etanercept had comparable effectiveness to MTX and sulfasalazine along with hydroxychloroquine. The RACAT trial used a cross-over design to switch patients for those who had failed their initial treatments at 24 weeks [13] . Factorial designs (TEAR), as well as crossover designs (RACAT) allow patients to receive alternative treatment options rather than simply drop out of the study,
KEY POINTS
New designs of head-to-head randomized clinical trials using active comparison groups provide high level evidence for comparative effectiveness research in RA.
Cluster randomized trials are increasingly used to compare the effectiveness of interventions that operate at a group level.
Indirect and network comparisons provide sophisticated methods for comparisons of RA medications when head-to-head trials are not available.
Observational studies have broad application for comparative effectiveness in RA with real-world nonexperimental data. but at the cost of added complexity and some challenges in interpretation of results. N-of-1 trials have been suggested to help decide on optimal treatments for patients when the treatments effects are rapid. N-of-1 trials are singlepatient experiments that incorporate multiple crossover periods wherein each patient receives a randomized sequence of treatments. At least two studies [14, 15] have applied this design to an RA population. Kravitz et al. [15] suggested that this study design may offer 'a better way to balance clinical judgment, consumer choice, and cost' after comparing different access models to expensive biologic therapies for the treatment of RA. Acceptability to patients and clinicians, as well as assumptions about rapidity of onset and washout between treatment periods, may pose some limitations in applying this trial design to RA. Nevertheless, despite a paucity of real-world applied examples in RA, N-of-1 trials remain a potentially promising study design option for some treatment regimens.
Cluster controlled trials
Cluster controlled trials (CCTs) are designed to evaluate interventions that operate at multiple levels and are used increasingly in public health related research, such as hospital and physicianbased studies. The rationale for a cluster-based trial is that an intervention is either directed at a physician or a bigger component of healthcare facility, like a hospital or could influence physician behaviour to such a degree that it would compromise the study's results if the clustering was ignored. Several CER-related CCT designs have been applied among patients with RA, including randomized cluster trials, nonrandomized but controlled cluster trials and multilevel cluster trials. Examples of these types of interventions in RA include strategy trials [e.g. a treat-to-target (T2T) trial], and a quality improvement trial.
The Consortium of Rheumatology Researchers of North America, Inc (CORRONA) has initiated a T2T trial, a multicentre cluster randomized trial in adults with RA [16] . This study is among the first in the United States to compare the effectiveness of the T2T approach for the care of RA vs. usual care. T2T requires frequent measurement of disease activity and prescribed treatment changes. The requirement for a cluster trial is that intervention physicians likely would become accustomed to aggressively treating both intervention patients and control patients alike. Therefore, participating sites (i.e. clusters) rather than individual patients were randomized to two treatments arms. Because measures collected from individuals of the same group tend to be more similar than individuals from different groups, the outcomes of patients from the same participating site are likely to be correlated, often measured as a nonzero intraclass correlation (ICC). This correlation will require a larger sample size and must be considered in designing such studies.
Desai et al. [17 & ] conducted a cluster controlled, nonrandomized trial that allocated physicians to intervention or control groups on the basis of the volume of patients in their practices. Fourteen rheumatologists were selected to receive a point-ofcare paper reminder form for patients who did not have pneumococcal vaccination, whereas the other 21 rheumatologists were selected not to receive the reminder form and served as controls. Although the nonrandom design was a limitation of this study [17 & ], intervention physicians had improvement in their patients being up to date with respect to pneumococcal vaccination (68-80%, P ¼ 0.006), whereas control physicians had no appreciable change in the same time frame (52% in both periods, P ¼ 0.90).
Some study designs may deploy interventions at the patient level but need to account for the practices of their treating physician. Warriner et al. [18] conducted a multilevel randomized trial to identify an intervention to improve osteoporosis screening with dual-energy x-ray absorptiometry (DXA) by offering patients the opportunity to self-schedule a DXA test. The trial included but was not limited to RA patients. Patients were randomized within physician practices and the intervention patients were compared with control patients within each practice. The results showed that mailing a simple educational osteoporosis brochure and allowing self-scheduling of a DXA scan significantly improve osteoporosis screening rates [18] . This study design that stratifies randomization within physician practices is useful when strong provider-level effects are expected and may be used in future studies, especially quality improvement studies, where the focus of interventions is not only on patients but also on physicians, allied healthcare providers (e.g. pharmacists) and health system related factors and barriers to care.
Large pragmatic trials
Compared with traditional clinical trials, pragmatic clinical trials (PCTs) are conducted in 'real-world' situations to compare the effectiveness of several treatments or treatment strategies. Strengths include randomization, efficiency because of modest primary data collection (hard outcomes) large sample sizes, high generalizing, minimal monitoring burden and suitability for safety assessment [19] . The efficiency of conducting PCTs in the United States was recently summarized [20 & ] and key design elements may include using community practices and engaging Practice Based Research Networks (PBRNs) to improve efficiency, effectiveness and generalizability of patient and provider site recruitment; simplifying enrollment procedures and data collection requirements, possibly through Internet technology using tablet PCs; and employing administrative data linkages to identify selected outcomes as key endpoints of the trial (especially safety outcomes), thus reducing cost and measurement burden for long-term followup. Administrative data include claims for medical services and prescription drugs, and including these linkages greatly simplifies collection of selected outcomes, important comorbidities, medication usage and drug adherence.
Application of these new methods was formative in the development of the Varicella Zoster Vaccine (VERVE) study protocol, a large pragmatic safety trial designed with support of the American College of Rheumatology Within Our Reach Program. A tablet PC is used to guide screening and facilitate patient-based data collection. Multiple health plan and registry databases were linked together to demonstrate trial feasibility and to assist in assessing long-term outcomes. RA patients were identified on the basis of physician diagnoses and receipt of antitumour necrosis factor (anti-TNF) therapy. Although the primary safety outcomes are clinical and immunologic, follow-up for longer term effectiveness outcomes to reduce herpes zoster risk is facilitated through a linkage with administrative claims data [21] . Trials conducted with safety outcomes in mind, as well as pharmacovigilance efforts, may be especially benefitted by such linkages between a clinical trial (or registry) and health plan, electronic health record, or administrative data.
Although not an RA-focused trial, the Post-Myocardial Infarction Free Rx Event and Economic Evaluation (MI FREEE) trial is another example of a large pragmatic trial. After discharge for myocardial infarction, participants were randomly assigned to full prescription coverage or usual prescription coverage. Patients in the full-coverage group had no cost sharing for any branded or generic statin, beta blocker, angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) for every prescription. As the randomization happened at the level of plan sponsor, all eligible beneficiaries in a plan received the same coverage. Using linked claims for filled prescriptions, procedures, physician encounters, hospitalizations and inpatient deaths, the investigators assessed outcomes (e.g. MI) using validated algorithms and medication adherence by using pharmacy data [22] . As adherence to RA medications may be in part related to medication costs, a trial designed to vary out-of-pocket patient costs of RA medications to improve adherence and outcomes could be used in future RA-related CER as a potential mechanism to overcome disparities in use of nonbiologic and biologic DMARDs.
SYNTHESIS OF EXISTING CLINICAL INFORMATION
Traditional systematic reviews and meta-analyses are often used to summarize the effects of an intervention against a single comparator group, usual placebo. As direct evidence from head-to-head comparison trials for RA medications is often unavailable, indirect comparison and network comparison were developed to provide more sophisticated methods for comparisons across several interventions [23, 24] . Indirect comparisons allow the synthesis of data using the relative effects of the several treatments vs. the common comparator. For example, a trial comparing treatment A vs. placebo and another trial comparing treatment B vs. placebo allow indirect comparison of treatment A vs. B. Network meta-analysis, sometimes used interchangeably with 'mixed treatment comparisons' when both direct and indirect evidence is available, is an extension of conventional meta-analysis and can incorporate multiple pairwise comparisons across a range of interventions and provide estimates of relative treatment effect [25] . Further variations on this method include mixed treatment comparisons using Bayesian approaches that seek to combine evidence from a-priori information and enhance confidence in the process of decision-making in CER analysis; published examples are available in RA [26] .
OBSERVATIONAL RESEARCH TO ADDRESS COMPARATIVE EFFECTIVENESS RESEARCH IN RHEUMATOID ARTHRITIS
Observational studies offer the ability to study outcomes of RA treatments in routine medical practice and fill critical gaps in RA CER [2] . Observational data sources to answer CER questions in RA include cohorts/registries, administrative claims and electronic medical records, each with strengths and limitations (Table 2) . CORRONA, the National Data Bank (NDB) for Rheumatic Diseases, the American College of Rheumatology's electronic health record-based Rheumatology Informatics System for Effectiveness (RISE) [27] and several large European registries in the UK, Sweden, Germany and Spain and other countries are examples of RA cohorts and registries that could be used for CER. Each of these data sources, as well as many others, are well positioned to contribute important comparative effectiveness data to the rheumatology community. Several examples from these registries directly comparing biologics with one another and identifying predictors of response have been recently published [28] [29] [30] .
Nested cohorts and learning networks
As a variation on a large disease registry, a nested cohort inside that registry can incorporate features of RCTs to study CER. For example, the recently launched CORRONA Comparative Effectiveness Registry to study Therapies for Arthritis and Inflammatory Conditions (CERTAIN) study uses the existing CORRONA network of participating sites to recruit new biologic users among RA patients. CERTAIN explicitly recruits patients on the basis of predefined explicit inclusion/exclusion criteria and establishes a new baseline for data collection when patients start or switch therapies. Other design features include systematic collection of RA disease activity measures at standardized intervals that are different from the parent cohort, a biospecimen repository, centrally run laboratory results, linkages with multiple external data sources and on-site monitoring for quality control.
As another example of a CER effort nested inside a disease registry, the Childhood Arthritis Rheumatology and Research Alliance (CARRA) network has developed consensus-based treatment protocols to understand the comparative effectiveness of diverse therapeutic options available for systemic juvenile idiopathic arthritis (JIA) and other conditions [31] . These protocols were designed to use best available evidence to minimize unwarranted heterogeneity in how patients are treated in order to generate comparative effectiveness data. Although currently deployed in an observational setting, randomization to one of these treatment protocols for specific patient types would be possible if needed to minimize confounding.
Administrative health plan and electronic health record data
Complementary to data from a disease registry, administrative claims data provided by governmental sources (e.g. the U.S. Center for Medicare and Medicaid Services) and commercial insurance companies include information on diagnoses, treatments, prescription drug use and outcome events for millions of beneficiaries. They are useful data sources for evaluation of CER of RA medications, especially with respect to studying rare safety events where large numbers of patients are needed.
Electronic medical records (EMRs) provide phenotypically richer information and include clinical details, medical history, patients' symptoms, the results of physical examinations and diagnostic tests [32] . The U.S. Veterans Health Administration healthcare system and Kaiser Permanente (a large U.S. managed care organization) are among the best examples of large healthcare systems and provider network sharing the same EMR system that could be used for CER.
Combining data for comparative effectiveness research analyses
Although the largest registries and health plan datasets contain a huge amount of information, each of them by themselves still may be too small to address key questions regarding rare exposures or outcomes.
Aggregating data across different data systems are therefore potentially useful. However, sharing of raw person-level data between data systems may be impractical or even impossible. As one example of a mechanism that pooled person-level data, projects can adopt common, standardized data formats across datasets to allow pooling of masked, person-level data. A recently published analysis examining biologic safety across a range of outcomes pooled four independent datasets together using such a distributed data model; individual identifiers were masked using propensity scores [33 & ,34]. The U.S. Mini-Sentinel project uses a similar distributed data model [35] .
Pooling and linking data sources together
Because administrative data typically lack detailed clinical information, linking an RA registry or cohort with other data sources may allow more valid assessment of exposures, confounders and outcomes. Standing linkages in some European countries between an RA cohort and a separate data source (e.g. cancer registry) provide such examples. Although these data sources are most easily linked through having a unique identifier, they may also be linked using multiple nonunique identifiers. More recently, several novel linkages between an RA registry and health plan data have been described. For example, Veterans Affairs (VA) RA registry (VARA) data have been collected by rheumatologists at 11 VHA facilities throughout the United States since 2003. With unique identifiers and patient consent, participants in VARA have been linked to both Veterans Health Administration's administrative databases (e.g. hospitalizations, pharmacy refills) and VHA EHR data. This type of linkage can facilitate CER in multiple ways; one recent example derived and validated a claims-based algorithm to determine the effectiveness of RA medications and compared it with a clinical gold standard (DAS28) available in the registry [36, 37] . This approach has been subsequently applied in very large datasets containing tens of thousands of RA patients to study the comparative effectiveness of various biologics for RA [38] . In addition, using a deterministic linkage on multiple, nonunique identifiers, the CORRONA registry has been linked with U.S. Medicare data to collect information regarding medication refills, hospitalizations, treatment-associated costs and other health services utilization [39] .
New methodologic approaches to analyzing comparative effectiveness research data observational data [40] . Propensity scores may be useful to control confounder and have been frequently used for observational studies of RA medications, especially when studying rare outcomes. On expectations, propensity scores balance observed covariates between exposed and comparator-treated patients, although propensity scores do not balance unmeasured confounders [41] . Variations on propensity scores may prove useful to extend this methodology. High-dimensional propensity scores (hd-PS) allow semi-automated variable selection using administrative data and may offer equal or better control of confounding than investigator-driven covariate selection [42] . When exposures are relatively rare (e.g. introduction of a new medication) and when outcomes are more common, or when there are multiple treatment groups to be compared, disease risk scores may serve a similar function to propensity scores and balance confounders by collapsing them into a single score, interpreted as the predicted risk for an outcome in the absence of the exposure of interest [43] . RA-specific disease risk scores have been derived and validated to estimate the risk of serious infections using clinical and administrative data [44, 45] . When time-depending confounding is particularly problematic, marginal structural models (MSMs) can be used to estimate the causal effect of a time-dependent exposure in the presence of time-dependent confounders affected by previous treatments. This approach has been applied to study the safety of RA medication in a longitudinal cohort in which complex relationships in changes in glucocorticoid dose, disease activity, functional status and medication discontinuation can be disentangled [46] . Finally, instrumental variable analysis is a method borrowed from health economics intended to reduce bias introduced by measured and unmeasured confounding. When unmeasured characteristics potentially bias results, instrumental variable analysis may provide a less biased estimate of treatment effects. Although instrumental variables have traditionally been limited to comparing only two treatments/interventions concurrently, a new approach has been developed to estimate multiple treatment effects [47, 48] .
CONCLUSION
This article reviews recent methods likely to prove useful for addressing CER questions in RA. These methods include head-to-head trials using active comparison groups, cluster controlled trials comparing the effectiveness of interventions that operate at a group level when the allocation of RA individual participants may not be desirable, large pragmatic trials using internet methods, network meta-analysis and related techniques to aggregate and summarize results. Variations on traditional disease-based registries include nesting subcohorts with more rigorous and standardized assessment and interventions, pooling and linking data sources together, and application of new analytic methods to control for confounding in observational studies. With these new methods, CER can help clinicians, patients and other stakeholders to assess the risks and benefits of various RA therapies to guide optimal decisions for individual patients.
